URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$44.09
−1.76%Margins
Gross margin
90.8%
EBITDA margin
-37.5%
EBIT margin
-35.3%
Net margin
-51.7%
FCF margin
-84.3%
73.7%
Return on equity
-38.7%
Return on assets
-104.6%
Return on invested capital
0.75x
Asset turnover
-$158.9M
Cash from operations
$2.21
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026